A probiotic combination attenuates experimental colitis through inhibition of innate cytokine production

Beneficial Microbes

Volumn 8, Issue 2, 2017, Pages 231-241

  Kim, M S ^a   Byun, J S ^a   Yoon, Y S ^a   Yum, D Y ^a   Chung, M J ^a   Lee, J C ^a  

^a Cellbiotech Co Ltd   (South Korea)

Author keywords

Experimental colitis; Inflammatory bowel disease; Innate pro inflammatory cytokines; Lactic acid bacteria; Probiotics

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1; INTERLEUKIN 6; MYELOPEROXIDASE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM BREVE; BODY WEIGHT; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; HISTOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINAL BLEEDING; LACTIC ACID BACTERIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOCOCCUS LACTIS; MALE; MOUSE; NONHUMAN; RAW 264.7 CELL LINE; STREPTOCOCCUS THERMOPHILUS; ANIMAL; BIFIDOBACTERIUM; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; CLASSIFICATION; COLITIS; DISEASE MODEL; DYSBIOSIS; IMMUNOLOGY; INFLAMMATION; INTESTINE FLORA; LACTOBACILLUS; METABOLISM;

ANIMALS; BIFIDOBACTERIUM; CELL LINE; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; INFLAMMATION; LACTOBACILLUS; MALE; MICE; MICE, INBRED C57BL; PROBIOTICS; RAW 264.7 CELLS; STREPTOCOCCUS THERMOPHILUS;

EID: 85018347087     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2016.0031     Document Type: Article

References (59)

1. Abraham, C. and Cho, J.H., 2009. Inflammatory bowel disease. New England Journal of Medicine 361: 2066-2078
2. Alp, G., Aslim, B., Suludere, Z. and Akca, G., 2010. The role of hemagglutination and effect of exopolysaccharide production on bifidobacteria adhesion to Caco-2 cells in vitro. Microbiology and Immunology 54: 658-665
3. Bai, A.P. and Ouyang, Q., 2006. Probiotics and inflammatory bowel diseases. Postgraduate Medical Journal 82: 376-382
4. Baumgart, D.C. and Sandborn, W.J., 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet 369: 1641-1657
5. Bibiloni, R., Fedorak, R.N., Tannock, G.W., Madsen, K.L., Gionchetti, P., Campieri, M., De Simone, C. and Sartor, R.B., 2005. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. American Journal of Gastroenterology 100: 1539-1546
6. Campieri, M. and Gionchetti, P., 2001. Bacteria as the cause of ulcerative colitis. Gut 48: 132-135
7. Chermesh, I. and Eliakim, R., 2006. Probiotics and the gastrointestinal tract: where are we in 2005? World Journal of Gastroenterology 12: 853-857
8. Clemente, J.C., Ursell, L.K., Parfrey, L.W. and Knight, R., 2012. The impact of the gut microbiota on human health: an integrative view. Cell 148: 1258-1270
9. Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J., 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation 69: 238-249
10. Cronin, M., Ventura, M., Fitzgerald, G.F. and Van Sinderen, D., 2011. Progress in genomics, metabolism and biotechnology of bifidobacteria. International Journal of Food Microbiology 149: 4-18
11. De Vos, W.M. and De Vos, E.A., 2012. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutrition Reviews 70, Suppl. 1: S45-S56
12. Del Piano, M., Balzarini, M., Carmagnola, S., Pagliarulo, M., Tari, R., Nicola, S., Deidda, F. and Pane, M., 2014. Assessment of the capability of a gelling complex made of tara gum and the exopolysaccharides produced by the microorganism Streptococcus thermophilus ST10 to prospectively restore the gut physiological barrier: a pilot study. Journal of Clinical Gastroenterology 48, Suppl. 1: S56-S61
13. Devkota, S., Wang, Y., Musch, M.W., Leone, V., Fehlner-Peach, H., Nadimpalli, A., Antonopoulos, D.A., Jabri, B. and Chang, E.B., 2012. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 487: 104-108
14. Ewaschuk, J.B. and Dieleman, L.A., 2006. Probiotics and prebiotics in chronic inflammatory bowel diseases. World Journal of Gastroenterology 12: 5941-5950
15. Frank, D.N. and Pace, N.R., 2008. Gastrointestinal microbiology enters the metagenomics era. Current Opinion in Gastroenterology 24: 4-10
16. Fuhrer, A., Sprenger, N., Kurakevich, E., Borsig, L., Chassard, C. and Hennet, T., 2010. Milk sialyllactose influences colitis in mice through selective intestinal bacterial colonization. Journal of Experimental Medicine 207: 2843-2854
17. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N.N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., Clarke, J.M., Topping, D.L., Tomita, M., Hori, S., Ohara, O., Morita, T., Koseki, H., Kikuchi, J., Honda, K., Hase, K. and Ohno, H., 2013. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446-450
18. Ghaleb, A.M., Bialkowska, A.B., Snider, A.J., Gnatenko, D.V., Hannun, Y.A., Yang, V.W. and Schmidt, V.A., 2015. IQ motif-containing GTPase-activating protein 2 (IQGAP2) is a novel regulator of colonic inflammation in mice. PLoS One 10: e0129314
19. Isolauri, E., Rautava, S. and Salminen, S., 2012. Probiotics in the development and treatment of allergic disease. Gastroenterology Clinics of North America 41: 747-762
20. Kaser, A., Lee, A.H., Franke, A., Glickman, J.N., Zeissig, S., Tilg, H., Nieuwenhuis, E.E., Higgins, D.E., Schreiber, S., Glimcher, L.H. and Blumberg, R.S., 2008. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 134: 743-756
21. Kaser, A., Zeissig, S. and Blumberg, R.S., 2010. Inflammatory bowel disease. Annual Review of Immunology 28: 573-621
22. Ko, S.J., Han, G., Kim, S.K., Seo, J.G., Chung, W.S., Ryu, B., Kim, J., Yeo, I., Lee, B.J., Lee, J.M. and Park, J.W., 2013. Effect of Korean herbal medicine combined with a probiotic mixture on diarrheadominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine 2013: 824605
23. Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C. and Schulze, J., 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623
24. Kumar, A., Hecht, C., Priyamvada, S., Anbazhagan, A.N., Alakkam, A., Borthakur, A., Alrefai, W.A., Gill, R.K. and Dudeja, P.K., 2014. Probiotic Bifidobacterium species stimulate human SLC26A3 gene function and expression in intestinal epithelial cells. American Journal of Physiology. Cell Physiology 307: C1084-1092
25. Lebeer, S., Vanderleyden, J. and De Keersmaecker, S.C., 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Reviews Microbiology 8: 171-184
26. Leone, V., Chang, E.B. and Devkota, S., 2013. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. Journal of Gastroenterology 48: 315-321
27. Luerce, T.D., Gomes-Santos, A.C., Rocha, C.S., Moreira, T.G., Cruz, D.N., Lemos, L., Sousa, A.L., Pereira, V.B., De Azevedo, M., Moraes, K., Cara, D.C., LeBlanc, J.G., Azevedo, V., Faria, A.M. and Miyoshi, A., 2014. Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis. Gut Pathogens 6: 33
28. MacDonald, T.T., Monteleone, G. and Pender, S.L., 2000. Recent developments in the immunology of inflammatory bowel disease. Scandinavian Journal of Immunology 51: 2-9
29. Madsen, K., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C., Doyle, J., Jewell, L. and De Simone, C., 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591
30. Marteau, P., Lemann, M., Seksik, P., Laharie, D., Colombel, J.F., Bouhnik, Y., Cadiot, G., Soule, J.C., Bourreille, A., Metman, E., Lerebours, E., Carbonnel, F., Dupas, J.L., Veyrac, M., Coffin, B., Moreau, J., Abitbol, V., Blum-Sperisen, S. and Mary, J.Y., 2006. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842-847
31. Mennigen, R., Nolte, K., Rijcken, E., Utech, M., Loeffler, B., Senninger, N. and Bruewer, M., 2009. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 296: G1140-1149
32. Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L., Baldassano, R.N. and Staiano, A., 2009. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. American Journal of Gastroenterology 104: 437-443
33. Nanda Kumar, N.S., Balamurugan, R., Jayakanthan, K., Pulimood, A., Pugazhendhi, S. and Ramakrishna, B.S., 2008. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. Journal of Gastroenterology and Hepatology 23: 1834-1839
34. Nielsen, O.H. and Munck, L.K., 2007. Drug insight: aminosalicylates for the treatment of IBD. Nature Clinical Practice Gastroenterology and Hepatology 4: 160-170
35. Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y. and Nakaya, R., 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702
36. Packey, C.D. and Sartor, R.B., 2009. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Current Opinion in Infectious Diseases 22: 292-301
37. Podolsky, D.K., 1991. Inflammatory bowel disease. New England Journal of Medicine 325: 928-937
38. Reiff, C. and Kelly, D., 2010. Inflammatory bowel disease, gut bacteria and probiotic therapy. International Journal of Medical Microbiology 300: 25-33
39. Riedel, C.U., Foata, F., Philippe, D., Adolfsson, O., Eikmanns, B.J. and Blum, S., 2006. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World Journal of Gastroenterology 12: 3729-3735
40. Santos Rocha, C., Lakhdari, O., Blottiere, H.M., Blugeon, S., Sokol, H., Bermudez-Humaran, L.G., Azevedo, V., Miyoshi, A., Dore, J., Langella, P., Maguin, E. and Van de Guchte, M., 2012. Antiinflammatory properties of dairy lactobacilli. Inflammatory Bowel Disease 18: 657-666
41. Sartor, R.B., 2006. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clinical Practice Gastroenterology and Hepatology 3: 390-407
42. Sartor, R.B., 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594
43. Shanahan, F., 2004. Probiotics in inflammatory bowel disease-therapeutic rationale and role. Advanced Drug Delivery Reviews 56: 809-818
44. Shanahan, F. and Collins, S.M., 2010. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterology Clinics of North America 39: 721-726
45. Sheil, B., Shanahan, F. and O'Mahony, L., 2007. Probiotic effects on inflammatory bowel disease. Journal of Nutrition 137: 819S-824S
46. Shen, D., Liu, C., Xu, R. and Zhang, F., 2012. Human gut microbiota: dysbiosis and manipulation. Frontiers in Cellular and Infection Microbiology 2: 123
47. Sokol, H., Seksik, P., Rigottier-Gois, L., Lay, C., Lepage, P., Podglajen, I., Marteau, P. and Dore, J., 2006. Specificities of the fecal microbiota in inflammatory bowel disease. Inflammatory Bowel Diseases 12: 106-111
48. Sood, A., Midha, V., Makharia, G.K., Ahuja, V., Singal, D., Goswami, P. and Tandon, R.K., 2009. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clinical Gastroenterology and Hepatology 7: 1202-1209
49. Stein, J., Hartmann, F. and Dignass, A.U., 2010. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 7: 599-610
50. Tannock, G.W., Munro, K., Harmsen, H.J., Welling, G.W., Smart, J. and Gopal, P.K., 2000. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Applied and Environmental Microbiology 66: 2578-2588
51. Toumi, R., Abdelouhab, K., Rafa, H., Soufli, I., Raissi-Kerboua, D., Djeraba, Z. and Touil-Boukoffa, C., 2013. Beneficial role of the probiotic mixture Ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis. Immunopharmacology and Immunotoxicology 35: 403-409
52. Tuohy, K.M., Rouzaud, G.C., Bruck, W.M. and Gibson, G.R., 2005. Modulation of the human gut microflora towards improved health using prebiotics-assessment of efficacy. Current Pharmaceutical Design 11: 75-90
53. Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G.M., Forti, G., Morini, S., Hassan, C., Pistoia, M.A., Modeo, M.E., Rodino, S., D'Amico, T., Sebkova, L., Sacca, N., Di Giulio, E., Luzza, F., Imeneo, M., Larussa, T., Di Rosa, S., Annese, V., Danese, S. and Gasbarrini, A., 2010. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. American Journal of Gastroenterology 105: 2218-2227
54. Velez, M.P., De Keersmaecker, S.C. and Vanderleyden, J., 2007. Adherence factors of Lactobacillus in the human gastrointestinal tract. FEMS Microbiology Letters 276: 140-148
55. Wescombe, P.A., Heng, N.C., Burton, J.P., Chilcott, C.N. and Tagg, J.R., 2009. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiology 4: 819-835
56. Yoon, H., Park, Y.S., Lee, D.H., Seo, J.G., Shin, C.M. and Kim, N., 2015. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Biochemistry and Nutrition 57: 129-134
57. Yoon, H., Yoon, Y.S., Kim, M.S., Chung, M.J. and Yum, D.Y., 2014a. A probiotic preparation duolac-gold ameliorates dextran sulphate sodium-induced mouse colitis by downregulating the expression of IL-6. Toxicology Research 30: 27-32
58. Yoon, J.S., Sohn, W., Lee, O.Y., Lee, S.P., Lee, K.N., Jun, D.W., Lee, H.L., Yoon, B.C., Choi, H.S., Chung, W.S. and Seo, J.G., 2014b. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Journal of Gastroenterology and Hepatology 29: 52-59
59. Zaki, M.H., Boyd, K.L., Vogel, P., Kastan, M.B., Lamkanfi, M. and Kanneganti, T.D., 2010. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32: 379-391